ENSC
ENSC
NASDAQ · Biotechnology

Ensysce Biosciences Inc

$0.35
-0.05 (-12.59%)
Financial Highlights (FY 2026)
Revenue
31.17M
Net Income
-62,593,891
Gross Margin
Profit Margin
-200.8%
Rev Growth
+26.2%
D/E Ratio
0.08
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.7% 48.7%
Operating Margin -202.1% -181.9% -7.6% -7.6%
Profit Margin -200.8% -190.8% -6.6% -5.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 31.17M 24.69M 257.5K 229.4K
Gross Profit 125.5K 111.8K
Operating Income -62,993,481 -44,920,476 -19,525 -17,347
Net Income -62,593,891 -44,635,529 -16,876 -13,616
Gross Margin 48.7% 48.7%
Operating Margin -202.1% -181.9% -7.6% -7.6%
Profit Margin -200.8% -190.8% -6.6% -5.9%
Rev Growth +26.2% +26.2% +2.0% +15.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 301.9K 301.9K 414.2K 358.8K
Total Equity 3.73M 3.73M 1.33M 1.24M
D/E Ratio 0.08 0.08 0.31 0.29
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -62,954,132 -47,386,439 -21,131 -19,685
Free Cash Flow -13,268 -16,406